First, doxorubicin could cause heart failure and reduce cardiomyocyte viability by promoting cell apoptosis and necroptosis in vivo and in vitro. Dexrazoxane prevents or reduces cardiac injury, as reflected by elevations in troponin t, that is associated with the use of doxorubicin for childhood all without. Study overview doxorubicin is an efficacious treatment for childhood acute lymphoblastic leukemia (all), but it is toxic to myocardial cells and can cause cardiomyopathy in this.
In this clinical trial, dexrazoxane, a. Dexrazoxane prevents or reduces cardiac injury, as reflected by elevations in troponin t, that is associated with the use of doxorubicin for childhood all without. Dexrazoxane prevents or reduces cardiac injury, as reflected by elevations in troponin t, that is associated with the use of doxorubicin for childhood all without.
Doxorubicin is an efficacious treatment for childhood acute lymphoblastic leukemia (all), but it is toxic to myocardial cells and can cause cardiomyopathy. Doxorubicin (dox) chemotherapy injures myocardial cells, leading to progressive cardiac dysfunction.